Context Therapeutics Inc (CNTX)

$2.22

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $2.20
    $2.28
    $2.22
    downward going graph

    0.9%

    Downside

    Day's Volatility :3.51%

    Upside

    2.63%

    downward going graph
  • $0.77
    $2.28
    $2.22
    downward going graph

    65.32%

    Downside

    52 Weeks Volatility :66.23%

    Upside

    2.63%

    downward going graph

Returns

PeriodContext Therapeutics IncIndex (Russel 2000)
3 Months
70.77%
0.0%
6 Months
133.68%
0.0%
1 Year
101.82%
0.0%
3 Years
-56.47%
-19.9%

Highlights

Market Capitalization
166.5M
Book Value
$0.53
Earnings Per Share (EPS)
-1.33
Wall Street Target Price
5.4
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-64.59%
Return On Equity TTM
-114.72%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-22.2M
Diluted Eps TTM
-1.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.69
EPS Estimate Next Year
-0.32
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Context Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 143.24%

Current $2.22
Target $5.40

Technicals Summary

Sell

Neutral

Buy

Context Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Context Therapeutics Inc
Context Therapeutics Inc
1.83%
133.68%
101.82%
-56.47%
-56.47%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Context Therapeutics Inc
Context Therapeutics Inc
NA
NA
NA
-0.69
-1.15
-0.65
NA
0.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Context Therapeutics Inc
Context Therapeutics Inc
Buy
$166.5M
-56.47%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Institutional Holdings

  • Opaleye Management Inc

    1.48%
  • Ally Bridge Group (NY) LLC

    0.97%
  • Vanguard Group Inc

    0.80%
  • Affinity Asset Advisors, LLC

    0.44%
  • UBS O'Connor LLC

    0.40%
  • ADAR1 Capital Management LLC

    0.27%

Company Information

context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.

Organization
Context Therapeutics Inc
Employees
5
CEO
Mr. Martin A. Lehr
Industry
Miscellaneous

FAQs